@article {45590,
	title = {Impairing powerhouse in colon cancer cells by hydrazide{\textendash}hydrazone-based small molecule},
	journal = {ACS omega },
	volume = {3},
	year = {2018},
	month = {FEB },
	pages = {1470{\textendash}1481},
	type = {Article },
	abstract = {Mitochondrion has emerged as one of the unconventional targets in next-generation cancer therapy. Hence, small molecules targeting mitochondria in cancer cells have immense potential in the next-generation anticancer therapeutics. In this report, we have synthesized a library of hydrazide{\textendash}hydrazone-based small molecules and identified a novel compound that induces mitochondrial outer membrane permeabilization by inhibiting antiapoptotic B-cell CLL/lymphoma 2 (Bcl-2) family proteins followed by sequestration of proapoptotic cytochrome c. The new small molecule triggered programmed cell death (early and late apoptosis) through cell cycle arrest in the G2/M phase and caspase-9/3 cleavage in HCT-116 colon cancer cells, confirmed by an array of fluorescence confocal microscopy, cell sorting, and immunoblotting analysis. Furthermore, cell viability studies have verified that the small molecule rendered toxicity to a panel of colon cancer cells (HCT-116, DLD-1, and SW-620), keeping healthy L929 fibroblast cells unharmed. The novel small molecule has the potential to form a new understudied class of mitochondria targeting anticancer agent.},
	issn = {2470-1343},
	doi = {10.1021/acsomega.7b01512},
	author = {Patil, S. and Kuman, M. M. and Palvai, S. and Sengupta, P. and Basu, S.}
}
